Welcome to our new website! If this is the first time you are logging in on the new site, you will need to reset your password. Please contact us at raps@raps.org if you need assistance.
The site navigation utilizes arrow, enter, escape, and space bar key commands. Left and right arrows move across top level links and expand / close menus in sub levels. Up and Down arrows will open main level menus and toggle through sub tier links. Enter and space open menus and escape closes them as well. Tab will move on to the next part of the site rather than go through menu items.
The regulatory function is vital in making safe and effective healthcare products available worldwide. Individuals who ensure regulatory compliance and prepare submissions, as well as those whose main job function is clinical affairs or quality assurance are all considered regulatory professionals.
Share your knowledge and expertise with your regulatory peers by submitting an in-depth, evidence-based article focusing on key areas and emerging issues in the global regulatory landscape.
One of our most valuable contributions to the profession is the Regulatory Code of Ethics. The Code of Ethics provides regulatory professionals with core values that hold them to the highest standards of professional conduct.
Your membership opens the door to free learning resources on demand. Check out the Member Knowledge Center for free webcasts, publications and online courses.
Like all professions, regulatory is based on a shared set of competencies. The Regulatory Competency Framework describes the essential elements of what is required of regulatory professionals at four major career and professional levels.
RAPS Euro Convergence brings regulatory peers from the EU and worldwide together in one forum to gain insights and exchange ideas on the region's most pressing issues. Register today to attend 10-12 May 2021.
Registration is now open for RAPS Convergence 2021! Gather with the regulatory community 12-15 September for four days of learning, engagement, and excitement.
With contributions from more than 30 authors from seven countries, the new edition incorporates a global overview of the field and is designed to help you get the most out of your regulatory intelligence endeavors.
Regipedia is an interactive resource created to benefit RAPS members with 24/7 access to more than 2,300 regulatory terms.
Hear from leaders around the globe as they share insights about their experiences and lessons learned throughout their certification journey.
The RAPS store will be under maintenance Saturday, 17 April between 5 AM and 12 PM EST. Store functionality may be unavailable at times during this window. We apologize for any inconvenience caused during this time.
Posted 01 February 2018 | By Michael Mezher
The European Medicines Agency (EMA) on Thursday released updated procedural advice on how it evaluates advanced therapy medicinal products (ATMPs) such as cell and gene therapies.
Alongside the updated advice document, EMA also released a new draft guideline on follow-up safety and efficacy requirements and risk management for ATMPs. According to EMA, the updated documents provide needed clarity to developers of ATMPs, who are often small or medium-sized enterprises (SMEs) or academic spinoffs that may need additional assistance navigating regulatory processes.
Both documents are also part of the joint action plan announced by EMA and the European Commission in October to bolster the development of advanced therapies.
EMA's procedural advice document for ATMPs was initially developed following discussions among the agency's scientific committees in 2009 and describes the evaluation process and review timetable for ATMPs, as well as the roles and responsibilities of the various rapporteurs and committees involved in the assessments.
EMA says the updated advice document serves to "streamline some procedural aspects, strengthen collaboration between EMA's scientific committees and address specific needs of ATMP developers in the initial marketing authorisations."
Specifically, EMA says it has streamlined the process for adopting the list of questions and outstanding issues generated by its committees and clarified when in-person responses to those questions or issues are needed.
Additionally, the revised procedure allows for longer "clock-stops" during the evaluation of ATMPs to give sponsors more time to respond to questions raised by EMA or its scientific committees.
EMA also launched a three-month public consultation on a revision to its guidelines on safety and efficacy follow-up and risk management for ATMPs.
By their nature, ATMPs are cutting edge products whose safety and efficacy may not always be fully known at the time of approval. As such EMA requires marketing authorization holders to follow a risk management plan and often requests that they complete additional postauthorization safety and efficacy studies.
EMA says the revised guideline is meant to strengthen and clarify its requirements for post-authorisation activities for ATMPs building on its experience with authorised advanced therapies over the last decade.
Specifically, EMA says the guideline provides new recommendations for detecting and mitigating risks and gives advice on postauthorization study design and methodology.
EMA, Procedural Advice, Follow-Up and Risk Management, Revised Guideline
Regulatory Focus newsletters
All the biggest regulatory news and happenings.